Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 13Unknown 8Recruiting 4Withdrawn 3Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Simvastatin × Clear all
NCT02096588 2024-07-09

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
34 enrolled 11 charts
Breast

Breast Neoplasms

NCT00575965 2015-12-16

Simvastatin in Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Terminated
18 enrolled 5 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡